Amicus Therapeutics (FOLD) | |||
---|---|---|---|
11.78 -0.08 (-0.67%) | 03-28 16:00 | ||
Open: | 11.87 | Pre. Close: | 11.86 |
High: | 11.93 | Low: | 11.485 |
Volume: | 2,399,468 | Market Cap: | 3,480(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 15.17 One year: 16.38 |
Support: | Support1: 11.32 Support2: 9.42 |
Resistance: | Resistance1: 12.99 Resistance2: 14.02 |
Pivot: | 11.75 |
Moving Averages: | MA(5): 11.63 MA(20): 12.06 MA(100): 12.36 MA(250): 12.22 |
MACD: | MACD(12,26): -0.35 Signal(12,26,9): -0.36 |
%K %D: | %K(14,3): 26.08 %D(3): 16.56 |
RSI: | RSI(14): 42.87 |
52-Week: | High: 14.57 Low: 9.7 Change(%): 8.0 |
Average Vol(K): | 3-Month: 3103 10-Days: 2643 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 11.958 - 12.017 | 12.017 - 12.064 |
Low: | 11.319 - 11.398 | 11.398 - 11.462 |
Close: | 11.668 - 11.789 | 11.789 - 11.888 |
Price, MAs and Bollinger Bands |
---|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FOLD ] has closed below upper band by 47.2%. Bollinger Bands are 51% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
Company profile |
---|
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. |
Stock chart |
---|
Financial Analysis | |
---|---|
Price to Book Value: | Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: NASDAQ Global Market | |
Sector: Healthcare | |
Industry: Biotechnology | |
Shares Out. (M) | 295.38 |
Shares Float (M) | 222.12 |
% Held by Insiders | 0.75 |
% Held by Institutions | 109.74 |
Shares Short (K) | 30910 |
Shares Short Prior Month (K) | 24400 |
Stock Financials | |
---|---|
EPS | -0.510 |
Book Value (p.s.) | 0.550 |
Profit Margin | -37.96 |
Operating Margin | -3.21 |
Return on Assets (ttm) | -6.1 |
Return on Equity (ttm) | -107.0 |
Qtrly Rev. Growth | 30.6 |
Gross Profit (p.s.) | |
Sales Per Share | 1.352 |
EBITDA (p.s.) | -0.222 |
Qtrly Earnings Growth | |
Operating Cash Flow (M) | -69.09 |
Levered Free Cash Flow (M) | -25.89 |
Stock Valuation | |
---|---|
PE Ratio | -23.10 |
PEG Ratio | |
Price to Book value | 21.42 |
Price to Sales | 8.71 |
Price to Cash Flow | -50.36 |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth |